Render Target: STATIC
Render Timestamp: 2024-10-04T10:33:33.807Z
Commit: f04ddd7fea9fb3592f59f61482fcb94610d25cbe
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

ABT-263 (Navitoclax) #79381

    Product Information

    Product Usage Information

    ABT-263 (Navitoclax) is supplied as a lyophilized powder. For a 5 mM stock, reconstitute 5 mg of powder in 1.0 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 974.6 g/mol
    Purity >98%
    Molecular Formula C47H55CIF3N5O6S3
    CAS 923564-51-6
    Solubility Soluble in DMSO at 25 mg/ml.

    Background

    ABT-263 (Navitoclax) is a potent and orally bioavailable Bcl-2 family inhibitor. This small molecule mimetic of BH3 domains specifically binds to Bcl-2, Bcl-xL, and Bcl-W with a Ki value of less than 1 nM (1). ABT-263 (Navitoclax) has been shown to have antitumor effects on small cell lung cancer (SCLC) xenograft models, resulting in complete tumor regression in some cases (2). Studies have shown that ABT-263 (Navitoclax) can enhance the effectiveness of chemotherapeutic and targeted agents against solid tumors (3). ABT-263 (Navitoclax) induces apoptosis, particularly in certain types of senescent cells (4,5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.